PhIII Trial PerioperativeVSAdj Chemothe Resectable PancreaticCa

Cancer
Jennifer Brooke Valerin
A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Pancreas

Study Description

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

Eligibility

-Patients must be 18 years of age or older

-Patients must have histologic or cytologic proof of pancreatic adenocarcinoma or adenosquamous carcinoma

  • Patients must not have prior radiation therapy, chemotherapy, targeting therapy, investigational therapy or surgery for pancreatic cancer

-Patients must not be pregnant or nursing

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.